BRADLEY K HIATT DO NPI 1841254406

NPI Details

Bradley K Hiatt, DO is a medical oncology internal medicine in Des Moines, IA with 29 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Bradley K Hiatt, DO NPI is 1841254406. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: DES MOINES UNIVERSITY OF OSTEOPATHIC MEDICINE AND HEALTH SCIENCES
Graduation Year:1997

The provider's business location address is:

411 LAUREL ST STE A300
DES MOINES, IA
ZIP 50314-030
Phone: (515) 282-2921
Fax: (515) 643-8819

The NPI 1841254406 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Phosphate level (HCPCS:84100)
• Uric acid level, blood (HCPCS:84550)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Ferritin (blood protein) level (HCPCS:82728)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Unclassified drugs (HCPCS:J3490)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Magnesium level (HCPCS:83735)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Automated urinalysis test (HCPCS:81003)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Hospital discharge day management, more than 30 minutes (HCPCS:99239)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Folic acid level, serum (HCPCS:82746)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)

The enumeration date for this NPI number is 4/12/2006 and was last updated on 11/18/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: